-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inhibition of asexual lymphoma kinase (ALK) is expected to be an effective therapy for ALK-positive malignancies.
Lymphoma
The study included patients with relapsed or refractory ALK-positive ALCL (6 years of age or older).
A total of 10 patients were enrolled, with a median age of 19.
In summary, aletinib shows good clinical activity and is well tolerated in ALK-positive ALCL patients who have progressed with standard chemotherapy.
Original source:
Reiji Fukano, Tetsuya Mori, et al.
Alectinib for relapsed or refractory anaplastic lymphoma kinase -positive anaplastic large cell lymphoma: An open-label phase II trial
in this message